Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17965080.
- Also identified by PMC identifier 2117133.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The use of anti-tumour necrosis factor (TNF) agents has expanded significantly over the past few years, particularly for rheumatological diseases and Crohn's disease. A number of associated opportunistic infections have been observed as a result of suppression of T cell-mediated immunity, the most frequent being tuberculosis. We report the first case of pulmonary actinomycosis in a patient receiving regular infusions of infliximab, an anti-TNF agent, for Crohn's disease.
Medical subject headings
- Actinomycosis
- Antibodies, Monoclonal
- Crohn Disease
- Gastrointestinal Agents
- Lung Diseases
- Opportunistic Infections